Zydus Lifesciences Ltd
NSE:ZYDUSLIFE

Watchlist Manager
Zydus Lifesciences Ltd Logo
Zydus Lifesciences Ltd
NSE:ZYDUSLIFE
Watchlist
Price: 964.8 INR -0.72% Market Closed
Market Cap: 970.8B INR
Have any thoughts about
Zydus Lifesciences Ltd?
Write Note

Zydus Lifesciences Ltd
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Zydus Lifesciences Ltd
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
Zydus Lifesciences Ltd
NSE:ZYDUSLIFE
Interest Income Expense
-â‚ą247m
CAGR 3-Years
38%
CAGR 5-Years
39%
CAGR 10-Years
11%
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Interest Income Expense
-â‚ą2.2B
CAGR 3-Years
-134%
CAGR 5-Years
-22%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Interest Income Expense
-â‚ą810.4m
CAGR 3-Years
17%
CAGR 5-Years
15%
CAGR 10-Years
5%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Interest Income Expense
â‚ą92m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Interest Income Expense
-â‚ą3B
CAGR 3-Years
1%
CAGR 5-Years
10%
CAGR 10-Years
-10%
M
Mankind Pharma Ltd
NSE:MANKIND
Interest Income Expense
â‚ą1.7B
CAGR 3-Years
21%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Zydus Lifesciences Ltd
Glance View

Market Cap
970.8B INR
Industry
Pharmaceuticals

Zydus Lifesciences Ltd., a resilient player in India's pharmaceutical industry, traces its origins back to 1952, when it was founded in Ahmedabad. Over the decades, it has metamorphosed from a modest venture into a global healthcare presence, with a diverse repertoire that spans across pharmaceuticals, animal health, and consumer wellness products. The company's ethos is deeply embedded in innovation, steadfastly pursuing research and development to propel its pipeline of generics, novel therapeutics, and vaccines. With a robust manufacturing infrastructure spread across continents, Zydus ensures seamless distribution and availability of its products, thereby maintaining a key foothold in both established and emerging markets. The lifeblood of Zydus's profitability streams from its comprehensive product portfolio, catering to a myriad of therapeutic areas such as cardiology, gastroenterology, and women's health, among others. It generates revenue primarily through the sale of branded generics and active pharmaceutical ingredients (APIs). Strategic alliances and collaborations further bolster its growth trajectory, providing new avenues for market expansion and technological advancements. As the firm continues to navigate the complex landscape of global healthcare demands, it remains anchored to its core mission of delivering accessible and affordable healthcare solutions, ensuring that it not only sustains its economic pulse but also positively impacts countless lives worldwide.

ZYDUSLIFE Intrinsic Value
675.81 INR
Overvaluation 30%
Intrinsic Value
Price

See Also

What is Zydus Lifesciences Ltd's Interest Income Expense?
Interest Income Expense
-247m INR

Based on the financial report for Sep 30, 2024, Zydus Lifesciences Ltd's Interest Income Expense amounts to -247m INR.

What is Zydus Lifesciences Ltd's Interest Income Expense growth rate?
Interest Income Expense CAGR 10Y
11%

The average annual Interest Income Expense growth rates for Zydus Lifesciences Ltd have been 38% over the past three years , 39% over the past five years , and 11% over the past ten years .

Back to Top